
- Pharmaceutical Executive-06-01-2009
- Volume 0
- Issue 0
Jean-Marc Huet, Bristol-Myers Squibb
There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face.
Jean-Marc Huet
CFO and Executive Vice President, Bristol-Myers Squibb
There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face. That's why BMS is executing a clear strategy to become a leading biopharma company while remaining focused on operational excellence and strengthening our balance sheet. What is needed now more than ever is the ability to turn challenges into opportunities; we're working to make sure BMS is well positioned to do so.
An innovative environment naturally creates leadership, and provides opportunities for successful, driven people. I make sure that the people whom I work with have what they need in order to be successful. We're all doers here, and that spirit will help us transform into the biopharma company we know we can be.
Articles in this issue
over 16 years ago
Hans Bishop, Bayer Healthcareover 16 years ago
Jennifer Spear Smith, Wyethover 16 years ago
Stefan Platz, Rocheover 16 years ago
Virginia Carden Carnahan, Vertex Pharmaceuticalsover 16 years ago
Jeffrey Tong, Infinity Pharmaceuticalsover 16 years ago
Elizabeth Mutisya, Solvay Pharmaceuticalsover 16 years ago
On the Right Pathwaysover 16 years ago
Craig Dashefsky, Schering-Ploughover 16 years ago
Joe Mclane, Merckover 16 years ago
Frank Karbe, ExelixisNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.